We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

The European Statistical Forum Announces its 4th Annual Conference

Read time: Less than a minute

The handling of missing data in clinical trials has become a crucial topic for clinical drug development in particular with respect to the regulatory process, as they are one of the most important sources of bias when analyzing clinical trials.

New methodologies and techniques have emerged like mixed-model repeated measures, multiple imputations, pattern-mixture models for longitudinal data as well as specific censoring rules and models for time to event data. As a consequence, regulatory agencies have published several documents related to the handling of missing data (e.g., Guideline on Missing Data in Confirmatory Clinical Trials EMA 02 July 2010).

Therefore, in order to achieve a successful drug registration, biostatisticians and clinical teams have to cope with the – often informative and dependant - nature of the missing data (not) observed in the trial.

The fourth conference of the European Statistical Forum is dedicated to theinvestigation, exploration as well as handling and analysis of missing data in clinical trials by presenting:

•    State-of-the art statistical methodology.
•    Real-life case studies of clinical trials showing how missing data can be handled and how they can impact trial results.
•    Regulatory viewpoints on this topic.

Thereby the conference aims at promoting the exchange of experts in the field coming from academia and industry as well as regulators.

Insights will be provided on the newest trends and on how to apply techniques for pivotal clinical trials as well as regulatory aspects related to this topic.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.